Platelet-Rich Plasma

Adrian D K Le; Lawrence Enweze; Malcolm R DeBaun; Jason L Dragoo

doi:10.1016/j.csm.2018.08.001

Platelet-Rich Plasma

Clin Sports Med. 2019 Jan;38(1):17-44. doi: 10.1016/j.csm.2018.08.001.

Authors

Adrian D K Le¹, Lawrence Enweze¹, Malcolm R DeBaun¹, Jason L Dragoo²

Affiliations

¹ Department of Orthopedic Surgery, Stanford University, 450 Broadway Street, Redwood City, CA 94063, USA.
² Department of Orthopedic Surgery, Stanford University, 450 Broadway Street, Redwood City, CA 94063, USA. Electronic address: jdragoo@stanford.edu.

PMID: 30466721
DOI: 10.1016/j.csm.2018.08.001

Abstract

Platelet-rich plasma (PRP) is a promising treatment for musculoskeletal maladies and clinical data to date have shown that PRP is safe. However, evidence of its efficacy has been mixed and highly variable depending on the specific indication. Additional future high-quality large clinical trials will be critical in shaping our perspective of this treatment option. The heterogeneity of PRP preparations, both presently and historically, leads sweeping recommendations about its utility impossible to make. This heterogeneity has also made interpreting existing literature more complicated.

Keywords: Augmentation; Orthobiologics; Osteoarthritis; PRP; Platelet-rich plasma; Regenerative medicine; Tendinopathy.

Publication types

Review

MeSH terms

Fractures, Bone / therapy*
Fractures, Ununited / therapy
Humans
Muscle, Skeletal / injuries*
Osteoarthritis / therapy*
Platelet-Rich Plasma*
Randomized Controlled Trials as Topic
Sprains and Strains / therapy*
Tendon Injuries / therapy*